21:43 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Emixustat: Ph IIa started

Kubota’s Acucela Inc. subsidiary began a blinded, U.S. Phase IIa trial to evaluate 2.5, 5 and 10 mg oral emixustat once daily for 1 month in about 30 patients. Kubota Pharmaceutical Holdings Co. Ltd. (Tokyo:4596),...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

Otsuka Pharmaceutical, Acucela deal

Otsuka terminated deals with Acucela to co-develop and co-commercialize Acucela’s emixustat ( ACU-4429 ) and Otsuka’s OPA-6566 . The emixustat deal was signed in 2008 and granted Otsuka co-development rights in North America and exclusive...
00:23 , Jun 15, 2016 |  BC Extra  |  Company News

Acucela slides after Otsuka ends ophthalmic deals

Acucela Inc. (Tokyo:4589) sank Y400 (24%) to Y1,253 on Tuesday after it said Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) terminated co-development deals for Acucela's emixustat (formerly ACU-4429 ) and Otsuka's OPA-6566 . Last month, Acucela...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Emixustat: Phase IIb/III data

Top-line data from the double-blind, U.S. Phase IIb/III S.E.A.T.T.L.E. trial in 508 patients with GA secondary to dry age-related AMD showed that once-daily 2.5, 5 and 10 mg oral emixustat each missed the primary endpoint...
00:56 , May 27, 2016 |  BC Extra  |  Clinical News

Acucela's emixustat fails in AMD study

Acucela Inc. (Tokyo:4589) dropped Y1,000 (17%) to Y4,790 after it said emixustat (formerly ACU-4429 ) missed the primary endpoint of the Phase IIb/III S.E.A.T.T.L.E. study to treat geographic atrophy (GA) in patients with age-related macular...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Emixustat: Phase II started

Acucela began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily oral emixustat for 12 weeks in 20 patients. Doses of emixustat will be doubled each week until week 4, after which patients will...
07:00 , May 2, 2016 |  BioCentury  |  Finance

Rational retail in Japan

The 2012 Japanese biotech bubble was fueled by irrational retail exuberance over a Nobel Prize awarded to a stem cell academic, but retail investors now are largely rewarding companies based on news events or upcoming...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

2Q milestones

2Q milestones Company Product Indication Event Milestone Ablynx N.V. (Euronext:ABLX) ALX-0171 Respiratory syncytial virus (RSV) infection Ph I/IIa data 2Q16 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Nuplazid pimavanserin Parkinson's disease psychosis (PDP) PDUFA date 5/1/16 Acucela Inc....
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....